Streamlining the Development and Validation Process in Discovery to Phase I Clinical Development

Pharma IQ

Reto Ossola, Group Leader for Biomarket Research at Biognosys, joins Helen Winsor from Pharma IQ, to discuss phase I clinical development. He outlines where he sees the main challenges in biomarker development at the moment and discusses some key ways to address the cost-efficiency pressures. The interview also takes a look at partnerships - Ossola offers some best practice tips on assessing and working with a CRO, together with a summary of the main challenges in selecting partners and ens...
To continue reading this story get free access